Age-related differences in disease characteristics and clinical outcomes in polycythemia vera

Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome

(2012) F. Giona et al.   BLOOD

The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis

(2011) J. H. Smalberg et al.   BLOOD

The JAK2 46/1 haplotype in splanchnic vein thrombosis

(2011) E. Kouroupi et al.   BLOOD

Polycythemia vera: gender-related phenotypic differences

(2011) Raffaele Landolfi et al.   Internal and Emergency Medicine

JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms

(2011) Laura Villani et al.   LEUKEMIA RESEARCH

Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis

(2011) Donatella Colaizzo et al.   THROMBOSIS RESEARCH

A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms

(2011) Hans Carl Hasselbalch   Expert Review of Hematology

Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders

(2010) B. L. Stein et al.   HAEMATOLOGICA

Treatment outcome in a cohort of young patients with polycythemia vera

(2010) Marco Ruggeri et al.   Internal and Emergency Medicine

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications

(2010) F Passamonti et al.   LEUKEMIA

JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy

(2010) Richard T. Silver et al.   LEUKEMIA RESEARCH

Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation

(2009) Valerio De Stefano et al.   ANNALS OF HEMATOLOGY

Clinical and hematological presentation of children and adolescents with polycythemia vera

(2009) Holger Cario et al.   ANNALS OF HEMATOLOGY

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients

(2009) Alberto Alvarez-Larrán et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera

(2009) Alfonso Quintás-Cardama et al.   JOURNAL OF CLINICAL ONCOLOGY

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

(2008) J.-J. Kiladjian et al.   BLOOD

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24 577 first-degree relatives of 11 039 patients with myeloproliferative neoplasms in Sweden

(2008) O. Landgren et al.   BLOOD

A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis

(2008) F. Passamonti et al.   BLOOD

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

(2008) J.-J. Kiladjian et al.   BLOOD

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

(2008) D. E. Rollison et al.   BLOOD

Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?

(2008) L. Teofili et al.   HAEMATOLOGICA